Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and /or fever

Patent metadata

Field	Value
Publication number	US-10640560-B2
Application number	US-201815987415-A
Country	US
Kind code	B2
Filing date	May 23, 2018
Priority date	Nov 25, 2008
Publication date	May 5, 2020
Grant date	May 5, 2020

Abstract

The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

First claim

What is claimed is:

1. A method of treating cardiac-related cachexia, respiratory-related cachexia, renal-related cachexia or age-related cachexia comprising administering to the patient an effective amount of an anti-IL-6 antibody or antibody fragment comprising variable heavy and variable light chain sequences respectively contained in SEQ ID NO:657 and SEQ ID NO:709.

2. The method of claim 1 , which further comprises detecting cardiac-related cachexia, respiratory-related cachexia, renal-related cachexia or age-related cachexia in the patient before, during or after antibody administration.

3. The method of claim 1 , wherein the cachexia comprises respiratory-related cachexia.

4. The method of claim 1 , wherein the cachexia comprises renal-related cachexia.

5. The method of claim 1 , wherein the cachexia comprises cardiac-related cachexia.

6. The method of claim 1 , wherein the cachexia comprises age-related cachexia.

7. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment comprises human IgG1 constant regions.

8. The method of claim 7 , wherein the human IgG1 constant region comprises the light constant chain polypeptide of SEQ ID NO: 586 and heavy constant chain polypeptide of SEQ ID NO:588.

9. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency of at most once per period of approximately four weeks.

10. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency of at most once per period of approximately eight weeks.

11. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency of at most once per period of approximately twelve weeks.

12. The method of claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency of at most once per period of approximately sixteen weeks.

Assignees

• Alderbio Holdings Llc

Inventors

• Smith Jeffrey T L
• Latham John A
• Litton Mark
• Schatzman Randall

Classifications

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• A61K2039/505

  comprising antibodies · CPC title